Literature DB >> 18974302

Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner.

Patricia G Wilson1, Joel C Thompson, Nancy R Webb, Frederick C de Beer, Victoria L King, Lisa R Tannock.   

Abstract

Inflammatory markers serum amyloid A (SAA) and C-reactive protein (CRP) are predictive of cardiac disease and are proposed to play causal roles in the development of atherosclerosis, in which the retention of lipoproteins by vascular wall proteoglycans is critical. The purpose of this study was to determine whether SAA and/or CRP alters vascular proteoglycan synthesis and lipoprotein retention in a pro-atherogenic manner. Vascular smooth muscle cells were stimulated with either SAA or CRP (1 to 100 mg/L) and proteoglycans were then isolated and characterized. SAA, but not CRP, increased proteoglycan sulfate incorporation by 50 to 100% in a dose-dependent manner (P < 0.0001), increased glycosaminoglycan chain length, and increased low-density lipoprotein (LDL) binding affinity (K(d), 29 microg/ml LDL versus 90 microg/ml LDL for SAA versus control proteoglycans; P < 0.005). Furthermore, SAA up-regulated biglycan via the induction of endogenous transforming growth factor (TGF)-beta. To determine whether SAA stimulated proteoglycan synthesis in vivo, ApoE(-/-) mice were injected with an adenovirus expressing human SAA-1, a null virus, or saline. Mice that received adenovirus expressing SAA had increased TGF-beta concentrations in plasma and increased aortic biglycan content compared with mice that received either null virus or saline. Thus, SAA alters vascular proteoglycans in a pro-atherogenic manner via the stimulation of TGF-beta and may play a causal role in the development of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18974302      PMCID: PMC2626400          DOI: 10.2353/ajpath.2008.080201

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  63 in total

1.  Oxidized low density lipoproteins regulate synthesis of monkey aortic smooth muscle cell proteoglycans that have enhanced native low density lipoprotein binding properties.

Authors:  M Y Chang; S Potter-Perigo; C Tsoi; A Chait; T N Wight
Journal:  J Biol Chem       Date:  2000-02-18       Impact factor: 5.157

2.  Elevated C-reactive protein levels in overweight and obese adults.

Authors:  M Visser; L M Bouter; G M McQuillan; M H Wener; T B Harris
Journal:  JAMA       Date:  1999-12-08       Impact factor: 56.272

3.  Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation.

Authors:  Karin Tran-Lundmark; Phan-Kiet Tran; Gabrielle Paulsson-Berne; Vincent Fridén; Raija Soininen; Karl Tryggvason; Thomas N Wight; Michael G Kinsella; Jan Borén; Ulf Hedin
Journal:  Circ Res       Date:  2008-07-03       Impact factor: 17.367

4.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

Authors:  P M Ridker; C H Hennekens; J E Buring; N Rifai
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

5.  The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease--baseline findings of the PAIS project.

Authors:  P Jousilahti; V Salomaa; V Rasi; E Vahtera; T Palosuo
Journal:  Atherosclerosis       Date:  2001-06       Impact factor: 5.162

6.  Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity.

Authors:  I Lemieux; A Pascot; D Prud'homme; N Alméras; P Bogaty; A Nadeau; J Bergeron; J P Després
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-06       Impact factor: 8.311

7.  Association between C-reactive protein and features of the metabolic syndrome: a population-based study.

Authors:  M Fröhlich; A Imhof; G Berg; W L Hutchinson; M B Pepys; H Boeing; R Muche; H Brenner; W Koenig
Journal:  Diabetes Care       Date:  2000-12       Impact factor: 19.112

8.  Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice.

Authors:  Z Mallat; A Gojova; C Marchiol-Fournigault; B Esposito; C Kamaté; R Merval; D Fradelizi; A Tedgui
Journal:  Circ Res       Date:  2001-11-09       Impact factor: 17.367

9.  Dietary cholesterol worsens adipose tissue macrophage accumulation and atherosclerosis in obese LDL receptor-deficient mice.

Authors:  Savitha Subramanian; Chang Yeop Han; Tsuyoshi Chiba; Timothy S McMillen; Shari A Wang; Antonio Haw; Elizabeth A Kirk; Kevin D O'Brien; Alan Chait
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-31       Impact factor: 8.311

10.  Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development.

Authors:  Fei Huang; Joel C Thompson; Patricia G Wilson; Hnin H Aung; John C Rutledge; Lisa R Tannock
Journal:  J Lipid Res       Date:  2007-11-21       Impact factor: 5.922

View more
  36 in total

1.  Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Zhe Dong; Tingting Wu; Weidong Qin; Chuankai An; Zhihao Wang; Mingxiang Zhang; Yun Zhang; Cheng Zhang; Fengshuang An
Journal:  Mol Med       Date:  2011-09-21       Impact factor: 6.354

Review 2.  Role of serum amyloid A in atherosclerosis.

Authors:  Preetha Shridas; Lisa R Tannock
Journal:  Curr Opin Lipidol       Date:  2019-08       Impact factor: 4.776

3.  Serum amyloid A3 is pro-atherogenic.

Authors:  Joel C Thompson; Patricia G Wilson; Preetha Shridas; Ailing Ji; Maria de Beer; Frederick C de Beer; Nancy R Webb; Lisa R Tannock
Journal:  Atherosclerosis       Date:  2017-11-17       Impact factor: 5.162

4.  Prevention of renal apoB retention is protective against diabetic nephropathy: role of TGF-β inhibition.

Authors:  Patricia G Wilson; Joel C Thompson; Meghan H Yoder; Richard Charnigo; Lisa R Tannock
Journal:  J Lipid Res       Date:  2017-09-14       Impact factor: 5.922

5.  Deficiency of Endogenous Acute-Phase Serum Amyloid A Protects apoE-/- Mice From Angiotensin II-Induced Abdominal Aortic Aneurysm Formation.

Authors:  Nancy R Webb; Maria C De Beer; Joanne M Wroblewski; Ailing Ji; William Bailey; Preetha Shridas; Richard J Charnigo; Victoria P Noffsinger; Jassir Witta; Deborah A Howatt; Anju Balakrishnan; Debra L Rateri; Alan Daugherty; Frederick C De Beer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-03-05       Impact factor: 8.311

6.  Localized thymic amyloidosis presenting with myasthenia gravis: case report.

Authors:  Seung-Myoung Son; Yong-Moon Lee; Si Wook Kim; Ok-Jun Lee
Journal:  J Korean Med Sci       Date:  2013-12-26       Impact factor: 2.153

7.  Increased atherosclerosis in mice with increased vascular biglycan content.

Authors:  Joel C Thompson; Tao Tang; Patricia G Wilson; Meghan H Yoder; Lisa R Tannock
Journal:  Atherosclerosis       Date:  2014-04-15       Impact factor: 5.162

8.  Inflammation, a link between obesity and cardiovascular disease.

Authors:  Zhaoxia Wang; Tomohiro Nakayama
Journal:  Mediators Inflamm       Date:  2010-08-05       Impact factor: 4.711

Review 9.  Currents concepts on the immunopathology of amyloidosis.

Authors:  Anupama Bhat; Carlo Selmi; Stanley M Naguwa; Gurtej S Cheema; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

10.  A murine model of obesity with accelerated atherosclerosis.

Authors:  Victoria L King; Nicholas W Hatch; Huei-Wei Chan; Marcielle C de Beer; Frederick C de Beer; Lisa R Tannock
Journal:  Obesity (Silver Spring)       Date:  2009-06-04       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.